Asked by: Jonathan Edwards (Independent - Carmarthen East and Dinefwr)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with the Welsh Government with regard to the international travel implications for British citizens who have received Covishield branded Astrazeneca covid-19 vaccinations.
Answered by Maggie Throup
We continue to have regular discussions with the devolved administrations on a range of issues.
AstraZeneca doses branded as ‘Covishield’ are not approved by the Medicines and Healthcare products Regulatory Agency and have not been administered in the United Kingdom. All doses of AstraZeneca COVID-19 vaccines administered in the UK are the same product, which appear on the NHS COVID Pass as Vaxzevria.
The Government continues to engage with other countries regarding certification to ensure that global travel is supported by a common approach.
Asked by: Jonathan Edwards (Independent - Carmarthen East and Dinefwr)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many doses of the Astrazeneca Covishield branded vaccines batches have been purchased by the Government and and how many have been used.
Answered by Maggie Throup
No doses of the AstraZeneca Covishield branded vaccines have been purchased by the Government. All AstraZeneca vaccine doses approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and administered in the United Kingdom were branded as the ’COVID-19 vaccine AstraZeneca’ which is now known commercially as ‘Vaxzeria’. The MHRA has not approved doses branded as ‘Covishield’ and none have been administered or rebranded as Vaxzevria in the UK. All AstraZeneca vaccines are the same product and appear on the NHS COVID Pass as Vaxzevria.
Asked by: Jonathan Edwards (Independent - Carmarthen East and Dinefwr)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether doses of the Astrazeneca Covishield have been rebranded as Vaxzevria upon distribution to UK citizens.
Answered by Maggie Throup
No doses of the AstraZeneca Covishield branded vaccines have been purchased by the Government. All AstraZeneca vaccine doses approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and administered in the United Kingdom were branded as the ’COVID-19 vaccine AstraZeneca’ which is now known commercially as ‘Vaxzeria’. The MHRA has not approved doses branded as ‘Covishield’ and none have been administered or rebranded as Vaxzevria in the UK. All AstraZeneca vaccines are the same product and appear on the NHS COVID Pass as Vaxzevria.
Asked by: Jonathan Edwards (Independent - Carmarthen East and Dinefwr)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when Ministers last met the (a) Food Standards Agency and (b) bodies representing businesses operating in the post farm gate meat processing sector to discuss issues relating to (i) the livestock industry in general and (ii) the functioning of abattoirs.
Answered by Jo Churchill
There have been no specific meetings on these issues.
Asked by: Jonathan Edwards (Independent - Carmarthen East and Dinefwr)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what support he is providing to innovative research into using psilocybin to treat depression.
Answered by Edward Argar
The Department, through the National Institute for Health Research (NIHR) has funded or supported various studies into the use of psilocybin to treat depression. The NIHR’s Research Programmes has invested £1.1 million in the study ‘A Feasibility RCT of Single-Dose Psilocybin in Unipolar Depressive Disorder Resistant to Standard Treatments’.